Literature DB >> 33244168

HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry.

Congwen Wei1, Luming Wan1, Qiulin Yan1,2, Xiaolin Wang1, Jun Zhang1, Xiaopan Yang1, Yanhong Zhang1, Chen Fan3, Dongyu Li1, Yongqiang Deng4, Jin Sun1, Jing Gong1,2, Xiaoli Yang5, Yufei Wang5, Xuejun Wang6, Jianmin Li1, Huan Yang1, Huilong Li1, Zhe Zhang1, Rong Wang1, Peng Du1, Yulong Zong7, Feng Yin7, Wanchuan Zhang8, Nan Wang8, Yumeng Peng1, Haotian Lin1, Jiangyue Feng1, Chengfeng Qin4, Wei Chen1, Qi Gao9, Rui Zhang10, Yuan Cao11, Hui Zhong12.   

Abstract

Responsible for the ongoing coronavirus disease 19 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through binding of the viral spike protein (SARS-2-S) to the cell-surface receptor angiotensin-converting enzyme 2 (ACE2). Here we show that the high-density lipoprotein (HDL) scavenger receptor B type 1 (SR-B1) facilitates ACE2-dependent entry of SARS-CoV-2. We find that the S1 subunit of SARS-2-S binds to cholesterol and possibly to HDL components to enhance viral uptake in vitro. SR-B1 expression facilitates SARS-CoV-2 entry into ACE2-expressing cells by augmenting virus attachment. Blockade of the cholesterol-binding site on SARS-2-S1 with a monoclonal antibody, or treatment of cultured cells with pharmacological SR-B1 antagonists, inhibits HDL-enhanced SARS-CoV-2 infection. We further show that SR-B1 is coexpressed with ACE2 in human pulmonary tissue and in several extrapulmonary tissues. Our findings reveal that SR-B1 acts as a host factor that promotes SARS-CoV-2 entry and may help explain viral tropism, identify a possible molecular connection between COVID-19 and lipoprotein metabolism, and highlight SR-B1 as a potential therapeutic target to interfere with SARS-CoV-2 infection.

Entities:  

Year:  2020        PMID: 33244168     DOI: 10.1038/s42255-020-00324-0

Source DB:  PubMed          Journal:  Nat Metab        ISSN: 2522-5812


  76 in total

Review 1.  Cellular host factors for SARS-CoV-2 infection.

Authors:  Jim Baggen; Els Vanstreels; Sander Jansen; Dirk Daelemans
Journal:  Nat Microbiol       Date:  2021-09-01       Impact factor: 17.745

2.  High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?

Authors:  Arnold von Eckardstein
Journal:  Handb Exp Pharmacol       Date:  2022

3.  SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas.

Authors:  Janis A Müller; Rüdiger Groß; Carina Conzelmann; Jana Krüger; Uta Merle; Johannes Steinhart; Tatjana Weil; Lennart Koepke; Caterina Prelli Bozzo; Clarissa Read; Giorgio Fois; Tim Eiseler; Julia Gehrmann; Joanne van Vuuren; Isabel M Wessbecher; Manfred Frick; Ivan G Costa; Markus Breunig; Beate Grüner; Lynn Peters; Michael Schuster; Stefan Liebau; Thomas Seufferlein; Steffen Stenger; Albrecht Stenzinger; Patrick E MacDonald; Frank Kirchhoff; Konstantin M J Sparrer; Paul Walther; Heiko Lickert; Thomas F E Barth; Martin Wagner; Jan Münch; Sandra Heller; Alexander Kleger
Journal:  Nat Metab       Date:  2021-02-03

4.  High plasma concentration of non-esterified polyunsaturated fatty acids is a specific feature of severe COVID-19 pneumonia.

Authors:  Maxime Nguyen; Abderrahmane Bourredjem; Lionel Piroth; Bélaïd Bouhemad; Antoine Jalil; Gaetan Pallot; Naig Le Guern; Charles Thomas; Thomas Pilot; Victoria Bergas; Hélène Choubley; Jean-Pierre Quenot; Pierre-Emmanuel Charles; Laurent Lagrost; Valerie Deckert; Jean-Paul Pais de Barros; Pierre-Grégoire Guinot; David Masson; Christine Binquet; Thomas Gautier; Mathieu Blot
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

Review 5.  SARS-CoV-2 cell entry and targeted antiviral development.

Authors:  Zinuo Chen; Ruikun Du; Jazmin M Galvan Achi; Lijun Rong; Qinghua Cui
Journal:  Acta Pharm Sin B       Date:  2021-05-13       Impact factor: 11.413

Review 6.  The Endothelium Is Both a Target and a Barrier of HDL's Protective Functions.

Authors:  Jérôme Robert; Elena Osto; Arnold von Eckardstein
Journal:  Cells       Date:  2021-04-28       Impact factor: 6.600

Review 7.  Cell entry by SARS-CoV-2.

Authors:  Ruchao Peng; Lian-Ao Wu; Qingling Wang; Jianxun Qi; George Fu Gao
Journal:  Trends Biochem Sci       Date:  2021-06-07       Impact factor: 13.807

Review 8.  Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19.

Authors:  Joshua R Cook; John Ausiello
Journal:  Rev Endocr Metab Disord       Date:  2021-07-01       Impact factor: 9.306

9.  Cholesterol Auxotrophy as a Targetable Vulnerability in Clear Cell Renal Cell Carcinoma.

Authors:  Nicolas Skuli; M Celeste Simon; Romain Riscal; Caroline J Bull; Clementina Mesaros; Jennifer M Finan; Madeleine Carens; Elaine S Ho; Jimmy P Xu; Jason Godfrey; Paul Brennan; Mattias Johansson; Mark P Purdue; Stephen J Chanock; Daniela Mariosa; Nicholas J Timpson; Emma E Vincent; Brian Keith; Ian A Blair
Journal:  Cancer Discov       Date:  2021-12-01       Impact factor: 38.272

10.  Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.

Authors:  Chaitra Prabhakara; Rashmi Godbole; Parijat Sil; Sowmya Jahnavi; Shah-E-Jahan Gulzar; Thomas S van Zanten; Dhruv Sheth; Neeraja Subhash; Anchal Chandra; Akshatha Shivaraj; Patricia Panikulam; Ibrahim U; Vijay Kumar Nuthakki; Theja Parassini Puthiyapurayil; Riyaz Ahmed; Ashaq Hussain Najar; Sai Manoz Lingamallu; Snigdhadev Das; Bhagyashri Mahajan; Praveen Vemula; Sandip B Bharate; Parvinder Pal Singh; Ram Vishwakarma; Arjun Guha; Varadharajan Sundaramurthy; Satyajit Mayor
Journal:  PLoS Pathog       Date:  2021-07-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.